AC Immune Says NLRP3 Inhibitor ACI-19764 Safe And Well Tolerated In Phase 1 With Confirmed CSF Penetration; Initial Cardiovascular Risk Cohort Results Expected By Year End

Loading news article.

AC Immune Says NLRP3 Inhibitor ACI-19764 Safe And Well Tolerated In Phase 1 With Confirmed CSF Penetration; Initial Cardiovascular Risk Cohort Results Expected By Year End | WAPE

AC Immune Says NLRP3 Inhibitor ACI-19764 Safe And Well Tolerated In Phase 1 With Confirmed CSF Penetration; Initial Cardiovascular Risk Cohort Results Expected By Year End

Article summary

Related companies

Comments —